Volta Medical, a health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists, announced the appointment of Bill Hoffman as Executive Chairman of its Board of Directors.

Bill brings a track record of guiding innovative startups to global success. As former Chief Executive Officer of Inari Medical, Hoffman oversaw the company's growth from early-stage concept to a publicly traded company with over USD 500 million in revenue and a significant clinical impact in venous thromboembolism treatment. Inari Medical was acquired by Stryker for $4.9B in February 2025.

"We are honored to welcome Bill Hoffman as Executive Chairman," said Théophile Mohr-Durdez, CEO and co-founder of Volta Medical. "Bill's experience building, commercializing, and scaling, disruptive medical technologies will be invaluable as we accelerate global access to our AI-driven solutions for cardiac ablation."

 "Volta's technology has demonstrated, for the first time in the history of ablation, a clinically important and statistically significant improvement in efficacy outcomes for patients with AFib", said Hoffman. "How cool is that? I am so excited to join the Volta team and mission to impact our patients in the most amazing ways". 

In addition to Bill's appointment, Volta's Board has also appointed Jerome Kalifa, MD, PhD to the role of Executive Vice Chairman. Dr Kalifa will also continue to serve in the role of Chief Medical Officer. "We are excited to work with Bill on this mission. We are committed to eliminating AFib, impacting as many patients as possible, as fast as possible," said Dr Kalifa.

This leadership appointment follows the recent publication of the landmark TAILORED-AF clinical trial in Nature Medicine, which demonstrated that an AI-guided procedure using Volta's technology, in combination with conventional pulmonary vein isolation (PVI), resulted in significantly improved outcomes for patients with persistent atrial fibrillation compared to PVI alone.